Probatebeta
Target

PDE4C

3',5'-cyclic-AMP phosphodiesterase 4C

As of the edition of 20 October 2026, PDE4C (3',5'-cyclic-AMP phosphodiesterase 4C, UniProt Q08493) has 25 drugs tested at it and 20 companies on the list, 7 on route A and 6 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q08493
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
Inside the cell
Solved structures
1
Disease areas
Skin and connective tissue; Lungs and airways; Immune system; Inherited and neonatal; Bones, joints and muscles; Nervous system; Infections; Nutrition and metabolism
Registered trials of its drugs
438

Drugs at this target

StatusCount
Marketed12
Active1
Went quiet8
Stopped3
Status not established1
Total25
DrugStatusFurthest phaseUS protection
ApremilastMarketedPhase 4Ends 2028
RoflumilastMarketedPhase 4none listed
Theophylline anhydrousMarketedPhase 4none listed
CrisaboroleMarketedPhase 4Ends 2029
EnsifentrineMarketedPhase 3Ends 2031
IbudilastMarketedPhase 3none listed
DifamilastMarketedPhase 3Ends 2036
TranimilastStoppedPhase 3none listed
GSK-256066Went quietPhase 2none listed
TetomilastStoppedPhase 3none listed
LotamilastWent quietPhase 2none listed
DovramilastActivePhase 2none listed

12 of 25 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A7
Route B6
Engaged4
Undetermined3
Total on the list20
Three companies on route A or B, with the route only
CompanyRoute
Chiesi FarmaceuticiRoute A
AstraZenecaRoute B
AmgenRoute B

The other 17 companies at PDE4C

In the product

20 companies in all; 17 are not named here, and no score is.

See the 20 companies at PDE4C, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at PDE4C

Other targets in skin and connective tissue

Companies holding approvals at PDE4C